The FDA may recommend long-term--or even permanent--use of nicotine-based quit-smoking aids, rather than the 12 weeks currently advised. The potential move is backed by anti-tobacco activists and GlaxoSmithKline, the leading marketer of nicotine-replacement therapy in the U.S. Report